関: hemagglutination、red blood cell agglutination

WordNet

agglutination of red blood cells (同)haemagglutination

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/10/11 17:53:20」(JST)

wiki en

Hemagglutination, or haemagglutination, is a specific form of agglutination that involves red blood cells (RBCs). It has two common uses in the laboratory: blood typing and the quantification of virus dilutions in a Haemagglutination assay.

Blood typing

Blood type can be determined by using antibodies that bind to the A or B blood group antigens in a sample of blood.

For example, if antibodies that bind the A blood group are added and agglutination occurs, the blood is either type A or type AB. To determine between type A or type AB, antibodies that bind the B group are added and if agglutination does not occur, the blood is type A. If agglutination does not occur with either antibodies that bind to type A or type B antigens, then neither antigen is present on the blood cells, which means the blood is type O.^[1]^[2]

In blood grouping, the patient's serum is tested against RBCs of known blood groups and also the patient's RBCs are tested against known serum types. In this way the patient's blood group is confirmed from both RBCs and serum. A direct Coombs test is also done on the patient's blood sample in case there are any confounding antibodies.

Viral hemagglutination assay

Many viruses attach to molecules present on the surface of RBCs. A consequence of this is that at certain concentrations, a viral suspension may bind together (agglutinate) the RBCs, thus preventing them from settling out of suspension. Since agglutination is not linked to infectivity, attenuated viruses can therefore be used in assays while an additional assay such as a plaque assay must be used to determine infectivity.

By serially diluting a virus suspension into an assay tray (a series of wells of uniform volume) and adding a standard amount of blood cells, an estimation of the number of virus particles can be made. While less accurate than a plaque assay, it is cheaper and quicker (taking just 30 minutes).

This assay may be modified to include the addition of an antiserum. By using a standard amount of virus, a standard amount of blood cells, and serially diluting the antiserum, one can identify the concentration of the antiserum (the greatest dilution which inhibits hemagglutination).

References

^ Muramatsu M, Gonzalez HD, Cacciola R, Aikawa A, Yaqoob MM, Puliatti C (2014). "ABO incompatible renal transplants: Good or bad?". WORLD JOURNAL OF TRANSPLANTATION. 4 (1): 18–29. doi:10.5500/wjt.v4.i1.18. PMID 11532188.
^ Rizzo C, Caruso C, Vasto S (2014). "Possible role of ABO system in age-related diseases and longevity: a narrative review". IMMUNOLOGY & AGING. 11: 16. doi:10.1186/1742-4933-11-16. PMC 4265994. PMID 25512760.

External links

Hemagglutination at the US National Library of Medicine Medical Subject Headings (MeSH)

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. ロスリバーウイルス感染 ross river virus infection
2. アデノウイルス感染の診断、治療、および予防 diagnosis treatment and prevention of adenovirus infection
3. 赤痢アメーバによる腸菅アメーバ症 intestinal entamoeba histolytica amebiasis
4. デング熱ウイルス感染症の臨床症状および診断 clinical manifestations and diagnosis of dengue virus infection
5. ペスト（Yersinia pestis感染症）の臨床症状、診断、および治療 clinical manifestations diagnosis and treatment of plague yersinia pestis infection

English Journal

Synthesis of multivalent sialyllactosamine-carrying glyco-nanoparticles with high affinity to the human influenza virus hemagglutinin.

Ogata M1, Umemura S2, Sugiyama N2, Kuwano N3, Koizumi A3, Sawada T4, Yanase M5, Takaha T5, Kadokawa J6, Usui T7.
Carbohydrate polymers.Carbohydr Polym.2016 Nov 20;153:96-104. doi: 10.1016/j.carbpol.2016.07.083. Epub 2016 Jul 20.
A series of multivalent sialoglyco-conjugated nanoparticles were efficiently synthesized by using highly-branched α-glucuronic acid-linked cyclic dextrins (GlcA-HBCD) as a backbone. The sialoglycoside-moieties, with varying degrees of substitution, could be incorporated onto the preformed nanoparti
PMID 27561476

Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.

Kang K1, Han S2, Hong T2, Jeon S2, Paek J2, Kang JH1,3, Yim DS4.
Yonsei medical journal.Yonsei Med J.2016 Nov;57(6):1354-60. doi: 10.3349/ymj.2016.57.6.1354.
PURPOSE: A phase I clinical trial was conducted to evaluate the immunogenicity and safety of newly developed egg-cultivated trivalent inactivated split influenza vaccine (TIV) in Korea.MATERIALS AND METHODS: The TIV was administered to 43 healthy male adults. Subjects with high pre-existing titers w
PMID 27593862

Preexisting Antibody-Dependent Cellular Cytotoxicity-Activating Antibody Responses Are Stable Longitudinally and Cross-reactive Responses Are Not Boosted by Recent Influenza Exposure.

Valkenburg SA1, Zhang Y2, Chan KY2, Leung K2, Wu JT2, Poon LL2.
The Journal of infectious diseases.J Infect Dis.2016 Oct 15;214(8):1159-63. doi: 10.1093/infdis/jiw346. Epub 2016 Aug 4.
Cross-reactive influenza virus-specific antibody-dependent cellular cytotoxicity (ADCC)-activating antibodies are readily detected in healthy adults. However, little is known about the kinetics of these ADCC responses. We used retrospective serial blood samples from healthy donors to investigate thi
PMID 27493238